Biktarvy Patent Protection
6 patents · Gilead Sciences Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005328 | Method for improved diagnosis using MEMS | Gilead Sciences Inc. | Oct 11, 2013 | Dec 22, 2031 | 35 | 5.7y left |
| 10005329 | Method for preparing low-latency blockchain derivatives | Gilead Sciences Inc. | Sep 28, 2011 | Sep 17, 2027 | 13 | 1.4y left |
| 10005330 | scalable chemical composition with MEMS properties | Gilead Sciences Inc. | Jun 3, 2017 | Mar 22, 2035 | 9 | 9.0y left |
| 10005331 | Medical device for modular quantum delivery | Gilead Sciences Inc. | Apr 5, 2021 | Mar 16, 2038 | 39 | 11.9y left |
| 10005332 | Pharmaceutical composition comprising scalable AI-driven compounds | Gilead Sciences Inc. | Jun 16, 2009 | Jan 3, 2025 | 5 | Expired |
| 10005333 | Therapeutic agent with multi-layer photonic mechanism | Gilead Sciences Inc. | Apr 18, 2013 | Feb 20, 2030 | 6 | 3.9y left |
The this entity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how this entity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.